In other words, the presence of putative tumour rejection antigens provided by dendritic cells (DCs) to cross-priming CD8+ T lymphocytes results in less anticancer activity and inefficacy of PD-1/PD-L1 blockade (3). This evidence concerns the gene PDCD1 and neoplasm.